Company: STAA
Filing Date: 2025-10-02
Form Type: DFAN14A
Source: 0001213900-25-095514
Chunk: 14

Company: STAAR SURGICAL CO
Filing Date: 2025-10-02
Form: DFAN14A
Chunk 14
---
 Products Enjoy Significant Advantages Over Alternatives ▪ Despite near - term, temporary headwinds to revenue growth and profitability, management remains “very bullish” 1 about the business over the long term and is confident in its ability to grow in existing and new markets ▪ With sales in China normalizing in the second half of 2025, growth continuing in other key markets, and margin initiatives ta kin g hold, management is forecasting a quick recovery in 2026 performance, followed by strong, double - digit expected growth in revenue and EBITDA through 2030 Management Has Expressed Confidence in STAAR’s Near - and Long - Term Opportunity 1 2 3 4 5 1. Source: STAAR Q1 2025 Earnings Call, May 7, 2025. B

Broadwood Partners, L.P. The Company’s Recent Financial Results Demonstrated Improvement 21 STAAR worked off excess inventory in China, delivered strong sales in other markets and reduced expenses ▪ STAAR’s financial results for Q2 2025 were strong and indicate that the Company is turning a corner — Revenue beat consensus, driven by double - digit year - over - year growth in the Americas and EMEA 3,4 — The Company meaningfully reduced costs 1 and expects to exit 2025 with SG&A expense run rate of approximately $225 million, an ~11% reduction from 2024 5 — Gross margins improved significantly 1 and are expected to return to historical levels once the Company’s new manufacturing facility in Switzerland is running at capacity 5 ▪ The Company disclosed in its Q2 2025 10 - Q that the level of inventory owned by its distributors in China had “decreased substantially” 3 since the beginning of the year and had “returned to historical levels” 3 — The Q2 2025 10 - Q also disclosed that the Company expects China revenue to normalize in the second half of 2025 3 ▪ Importantly, these promising results were not disclosed until the day after the Merger was announced, because Alcon insisted on a fast signing — We believe STAAR’s Q2 2025 earnings would have served as a catalyst for the stock to re - rate 1. Source: STAAR Annual and Quarterly Reports on Form 10 - K and 10 - Q, respectively. 2. Source: STAAR Investor Presentation, filed with the SEC on June 4, 2025. 3. Source